Published in Br J Pharmacol on January 05, 2004
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci (2011) 2.31
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol (2005) 1.38
The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond. Cell Mol Life Sci (2012) 1.16
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol (2004) 0.99
Fatty acid amide signaling molecules. Bioorg Med Chem Lett (2010) 0.98
The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther (2009) 0.95
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther (2013) 0.92
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol (2006) 0.90
The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. Eur J Pharmacol (2011) 0.85
Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. Neuropharmacology (2008) 0.83
α-Ketoheterocycle-based Inhibitors of Fatty Acid Amide Hydrolase (FAAH). ACS Chem Neurosci (2011) 0.83
The Endocannabinoid System in the Postimplantation Period: A Role during Decidualization and Placentation. Int J Endocrinol (2013) 0.83
Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. Eur J Pharmacol (2009) 0.82
Oleamide: a member of the endocannabinoid family? Br J Pharmacol (2003) 0.81
The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics (2015) 0.80
The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci (2016) 0.79
Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem (2007) 0.79
Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro. Lipids Health Dis (2012) 0.78
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity. Int J Neuropsychopharmacol (2015) 0.77
Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug? Neurotox Res (2015) 0.75
Endocannabinoid system: Role in depression, reward and pain control (Review). Mol Med Rep (2016) 0.75
Passiflora incarnata attenuation of neuropathic allodynia and vulvodynia apropos GABA-ergic and opioidergic antinociceptive and behavioural mechanisms. BMC Complement Altern Med (2016) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther (1997) 5.20
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 2.95
Chemical characterization of a family of brain lipids that induce sleep. Science (1995) 2.69
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci (1997) 2.25
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids (2002) 2.15
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther (2002) 2.01
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci U S A (2000) 1.89
Anandamide may mediate sleep induction. Nature (1997) 1.53
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Curr Med Chem (1999) 1.51
'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta (1998) 1.43
Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol (2002) 1.40
A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol (1996) 1.35
Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther (1998) 1.31
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther (2001) 1.31
Fatty acid amide hydrolase substrate specificity. Bioorg Med Chem Lett (2000) 1.30
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des (1998) 1.28
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors. Proc Natl Acad Sci U S A (1996) 1.22
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther (1998) 1.20
Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem (1995) 1.16
Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp Neurol (2001) 1.11
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci (1996) 1.10
Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem (1999) 1.07
Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology (1999) 1.06
Anandamide modulates sleep and memory in rats. Brain Res (1998) 1.04
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun (1997) 1.00
Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci U S A (1997) 1.00
Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol (2001) 0.99
Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J Pharmacol Exp Ther (2001) 0.98
Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids (2002) 0.95
A separation method for the assay of adenylylcyclase, intracellular cyclic AMP, and cyclic-AMP phosphodiesterase using tritium-labeled substrates. Anal Biochem (1992) 0.90
The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. Neuroreport (1999) 0.89
The endogenous lipid oleamide activates serotonin 5-HT7 neurons in mouse thalamus and hypothalamus. J Neurochem (1999) 0.88
Enzymatic synthesis of oleamide (cis-9, 10-octadecenoamide), an endogenous sleep-inducing lipid, by rat brain microsomes. Biochem Mol Biol Int (1996) 0.86
Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol (1999) 0.86
Arachidonic acid amide inhibitors of gap junction cell-cell communication. Bioorg Med Chem Lett (1999) 0.85
CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. J Neurosci Res (2001) 0.85
The sleep hormone oleamide modulates inhibitory ionotropic receptors in mammalian CNS in vitro. Br J Pharmacol (2002) 0.83
Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A. Neuroreport (1996) 0.83
Oleamide modulates memory in rats. Neurosci Lett (2001) 0.82
Deletion of the GABA(A) receptor beta 3 subunit eliminates the hypnotic actions of oleamide in mice. Neuroreport (2001) 0.82
Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids (1996) 0.81
Studies on the sedative and hypnotic effects of oleamide in mice. Arzneimittelforschung (1999) 0.77
The sleep inducing brain lipid cis-oleamide (cOA) does not modulate serotonergic transmission in the CA1 pyramidal neurons of the hippocampus in vitro. Neuropharmacology (2004) 0.77
Early events in preprotein recognition in E. coli: interaction of SRP and trigger factor with nascent polypeptides. EMBO J (1995) 2.38
Signal peptides: exquisitely designed transport promoters. Mol Microbiol (1994) 2.28
Inositol phospholipid hydrolysis in rat cerebral cortical slices: I. Receptor characterisation. J Neurochem (1984) 2.26
An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun (1996) 1.99
Nascent membrane and presecretory proteins synthesized in Escherichia coli associate with signal recognition particle and trigger factor. Mol Microbiol (1997) 1.85
The purification and properties of myo-inositol monophosphatase from bovine brain. Biochem J (1988) 1.80
The dephosphorylation of inositol 1,4-bisphosphate to inositol in liver and brain involves two distinct Li+-sensitive enzymes and proceeds via inositol 4-phosphate. Biochem J (1988) 1.49
No role for phospholipase A2 and protein kinase C in the potentiation by alpha-adrenoceptors of beta-adrenoceptor-mediated cyclic AMP formation in rat brain. J Neurochem (1989) 1.45
Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl) (2011) 1.44
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology (2009) 1.39
Artificial transmembrane segments. Requirements for stop transfer and polypeptide orientation. J Biol Chem (1995) 1.38
'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci (1998) 1.37
A fluorescence assay to monitor vesicle fusion and lysis. J Biol Chem (1982) 1.34
Idealization of the hydrophobic segment of the alkaline phosphatase signal peptide. Nature (1986) 1.34
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol (2000) 1.32
Titration of protein transport activity by incremental changes in signal peptide hydrophobicity. Biochemistry (1993) 1.26
Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol (1997) 1.26
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol Sci (1998) 1.20
Studies on the adenosine-receptor mediating the augmentation of histamine-induced inositol phospholipid hydrolysis in guinea-pig cerebral cortex. Br J Pharmacol (1987) 1.19
Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology (2003) 1.17
Inositol phospholipid hydrolysis in rat cerebral cortical slices: II. Calcium requirement. J Neurochem (1984) 1.16
Synthetic signal peptides specifically recognize SecA and stimulate ATPase activity in the absence of preprotein. J Biol Chem (1998) 1.16
Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol Biochem Behav (1998) 1.15
Signal peptide determinants of SecA binding and stimulation of ATPase activity. J Biol Chem (2000) 1.15
Differences in the adenosine receptors modulating inositol phosphates and cyclic AMP accumulation in mammalian cerebral cortex. Br J Pharmacol (1989) 1.15
5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants. J Pharmacol Exp Ther (1985) 1.15
Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. J Neurochem (1988) 1.14
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 1.14
Cannabinoids and PPARalpha signalling. Biochem Soc Trans (2006) 1.13
Surface engineering of living myoblasts via selective periodate oxidation. Biotechnol Bioeng (2003) 1.13
Mapping of nucleoside phosphorylase (Np-1) and esterase 10 (Es-10) on mouse chromosome 14. Biochem Genet (1977) 1.11
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord (1998) 1.10
Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Eur J Pharmacol (1998) 1.10
Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol (2001) 1.09
Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl) (2000) 1.09
Cross-talk between different receptor-effector systems in the mammalian CNS. Cell Signal (1989) 1.09
Functional limits of conformation, hydrophobicity, and steric constraints in prokaryotic signal peptide cleavage regions. Wild type transport by a simple polymeric signal sequence. J Biol Chem (1991) 1.08
Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem (1999) 1.07
Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem (1997) 1.07
Detergent effects on enzyme activity and solubilization of lipid bilayer membranes. Biochim Biophys Acta (1983) 1.07
Dopaminergic and serotonergic function following isolation rearing in rats: study of behavioural responses and postmortem and in vivo neurochemistry. Pharmacol Biochem Behav (1992) 1.07
Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology (1999) 1.06
Sendai virus-mediated lysis of liposomes requires cholesterol. Proc Natl Acad Sci U S A (1983) 1.05
Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci (2008) 1.04
Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology (2003) 1.04
Role of gap junctions in endothelium-derived hyperpolarizing factor responses and mechanisms of K(+)-relaxation. Eur J Pharmacol (2000) 1.03
Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Eur J Pharmacol (1997) 1.02
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun (2005) 1.01
Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci (2000) 1.01
Characterization of a fluorescence assay to monitor changes in the aqueous volume of lipid vesicles. Anal Biochem (1983) 1.00
Dihydropyridine calcium channel activators and antagonists influence depolarization-evoked inositol phospholipid hydrolysis in brain. Eur J Pharmacol (1985) 0.99
Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem (1998) 0.98
[3H]quaternised ICS 205-930 labels 5-HT3 receptor binding sites in rat brain. Eur J Pharmacol (1988) 0.98
Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci (2004) 0.97
A comparison of A2 adenosine receptor-induced cyclic AMP generation in cerebral cortex and relaxation of pre-contracted aorta. Br J Pharmacol (1994) 0.97
Examination of the role of inhibition of cyclic AMP in alpha 2-adrenoceptor mediated contractions of the porcine isolated palmar lateral vein. Br J Pharmacol (1995) 0.96
Signal peptide cleavage regions. Functional limits on length and topological implications. J Biol Chem (1994) 0.96
Polymeric sequences reveal a functional interrelationship between hydrophobicity and length of signal peptides. J Biol Chem (1990) 0.96
Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. J Pharmacol Exp Ther (1987) 0.96
A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex. Br J Pharmacol (1994) 0.94
Agonist-induced changes in [Ca2+]i in N1E-115 cells: differential effects of bradykinin and carbachol. Eur J Pharmacol (1992) 0.94
Adenosine receptor-induced second messenger production in adult guinea-pig cerebellum. Br J Pharmacol (1993) 0.94
Physical and conformational properties of synthetic idealized signal sequences parallel their biological function. Biochemistry (1995) 0.94
Alpha 1-adrenoceptor-mediated inositol phospholipid hydrolysis in rat cerebral cortex: relationship between receptor occupancy and response and effects of denervation. Eur J Pharmacol (1985) 0.94
Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br J Pharmacol (2001) 0.93
Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion. J Psychopharmacol (2008) 0.93
Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.92
Central c-fos expression following 20kHz/ultrasound induced defence behaviour in the rat. Brain Res Bull (1997) 0.92
Receptors and phosphoinositide metabolism in the central nervous system. Biochem Pharmacol (1986) 0.91
Pirenzepine indicates heterogeneity of muscarinic receptors linked to cerebral inositol phospholipid metabolism. Neuropharmacology (1985) 0.91
Alpha2-adrenoceptor-mediated contractions of the porcine isolated ear artery: evidence for a cyclic AMP-dependent and a cyclic AMP-independent mechanism. Br J Pharmacol (1998) 0.91
Protein transport via amino-terminal targeting sequences: common themes in diverse systems. Mol Membr Biol (1996) 0.90
Species-selective binding of [3H]-idazoxan to alpha 2-adrenoceptors and non-adrenoceptor, imidazoline binding sites in the central nervous system. Br J Pharmacol (1993) 0.90
Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids. Br J Pharmacol (2010) 0.90
Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol (2001) 0.89
Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci (2009) 0.89
Use of site-directed mutagenesis to elucidate the role of arginine-166 in the catalytic mechanism of alkaline phosphatase. Proc Natl Acad Sci U S A (1988) 0.89
Transport of an export-defective protein by a highly hydrophobic signal peptide. J Biol Chem (1994) 0.88
Expression of beta 2-adrenoceptors mediating cyclic AMP accumulation in astroglial and neuronal cell lines derived from the rat CNS. Biochem Pharmacol (1990) 0.88
Characterization of cannabinoid receptors coupled to vasorelaxation by endothelium-derived hyperpolarizing factor. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.88
The effects of acute and chronic lithium treatment on pilocarpine-stimulated phosphoinositide hydrolysis in mouse brain in vivo. Br J Pharmacol (1990) 0.87
Inhibition of forskolin-stimulated cyclic AMP formation by 1-aminocyclopentane-trans-1,3-dicarboxylate in guinea-pig cerebral cortical slices. J Neurochem (1992) 0.87
Sec-dependent protein export and the involvement of the molecular chaperone SecB. Cell Stress Chaperones (2000) 0.87
Enhanced catalysis by active-site mutagenesis at aspartic acid 153 in Escherichia coli alkaline phosphatase. Biochemistry (1992) 0.87
Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis. Neuropharmacology (2010) 0.87
The amino-terminal charge and core region hydrophobicity interdependently contribute to the function of signal sequences. J Biol Chem (1996) 0.87
Inositol 1,4,5-trisphosphate generation and calcium mobilisation via activation of an atypical P2 receptor in the neuronal cell line, N1E-115. Br J Pharmacol (1992) 0.87
Central noradrenergic depletion by DSP-4 prevents stress-induced memory impairments in the object recognition task. Neuroscience (2009) 0.86
Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. Neuropharmacology (2003) 0.86
Discriminatory effects of forskolin and EGTA on the indirect cyclic AMP responses to histamine, noradrenaline, 5-hydroxytryptamine, and glutamate in guinea-pig cerebral cortical slices. J Neurochem (1990) 0.85
Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience (2000) 0.85
Inositol phospholipid hydrolysis and potentiation of cyclic AMP formation by noradrenaline in rat cerebral cortex slices are not mediated by the same alpha-adrenoceptor subtypes. J Neurochem (1989) 0.85
Is Ffh required for export of secretory proteins? FEBS Lett (2001) 0.85
Properties of 3H-cimetidine binding in rat brain membrane fractions. Life Sci (1980) 0.85